米托蒽醌为主的化疗方案对CD34^+高表达急性髓细胞性白血病疗效观察  

The clinical studies of mitoxantrone in acute myelogenous leukemia with high percentage of CD34^+

作　　者：凌云[1] 曹祥山[1] 邱国强[1] 谢晓宝[1] 刘琰[1] 顾伟英[1] 钱新瑜[1] 

机构地区：[1]常州市第一人民医院苏州大学附属第三医院血液科,江苏常州213003

出　　处：《临床血液学杂志》2005年第2期84-86,共3页Journal of Clinical Hematology

摘　　要：目的:探索米托蒽醌(MTZ)在急性髓细胞性白血病(AML)化疗中的作用特点,提高AML的疗效和无病生存率(FDS)。方法:80例免疫分型中有CD34+ 抗原高表达的AML,随机选择(MA/MAE、DA/DAE和HA/HAE)方案,联合化疗1~2个疗程后分别比较CR率、骨髓抑制及其它毒副作用;同时对白血病细胞进行体外药物杀伤效应实验,分别比较MTZ、柔红霉素(DNR)、高三尖杉酯碱(HHT)对白血病细胞不同分化阶段的抑制作用。结果:CD34抗原高表达的AML中,1~2 个疗程CR率,以MA/MAE方案最高,为80.0%(24/30),白血病细胞体外药物杀伤实验显示,MTZ对CD34+高表达的AML的抑制显著高于DNR和HHT。结论:MTZ具有较强的抗AML活性,临床骨髓抑制明显上述特点可能与其主要作用于AML白血病细胞的分化较早阶段有关。Objective:To investigate the character of antitumor effects of mitoxantrone (MTZ) and increase the remission rate and disease-free survivals (DFS) in acute myelogenous leukemia (AML).Method:80 AML patients with high percentage CD34+ was randomly divided into receiving MA/MAE, DA/DAE or HA/HAE induction chemotherapy regimen and evaluate the efficacy and safety. The killing effects of MTZ were investigated by in vitro culturing leukemia cells from patients through MTT assay.Result:there are 80.0%(24/30) of patients in AML with regimen MA/MAE achieved remission after induction alone, higher remission rate than those regimens containing DNR and HTT. A Higher inhibition on leukemia cells with high percentage of CD34+ in vitro was seen with MTZ than with DNR and HTT.Conclusion:MTZ had a strong anti-leukoumia effect. The significant bone marrow suppression of MTZ might relate with MTZ's effect mainly on early differentiation phase of leukemia cell.

关 键 词：白血病 急性 米托蒽醌 CD34^+ 

分 类 号：R733.71[医药卫生—肿瘤]